Live Attenuated and Killed Vaccine Solution
At Creative Biolabs, we specialize in comprehensive preclinical design services for live attenuated and inactivated/killed vaccines. Leveraging our deep understanding of microbial infection mechanisms and immune responses, we meticulously engineer live attenuated vaccines that closely mimic natural infections, thereby triggering robust immune responses often leading to lifelong immunity. Simultaneously, we excel in designing inactivated vaccines, emphasizing stability and safety, making them ideal for individuals with immunodeficiency. Our extensive expertise spans from attenuating pathogens to developing fractional vaccines and adjuvants, ensuring our clients have access to cutting-edge vaccine design solutions for their research endeavors.
Talk To Our Vaccine Experts View Services Available products
What is live attenuated and killed vaccine?
A live attenuated vaccine is created by reducing the virulence of a pathogen while keeping it viable. These vaccines are derived from wild viruses or bacteria that have been weakened through repeated culturing. They mimic natural infections, triggering strong cellular and antibody responses, often providing lifelong immunity with just one or two doses. Examples include vaccines for measles, mumps, and chickenpox. On the other hand, inactivated/killed vaccines consist of whole viruses or bacteria, or their fractions, that have been killed using physical or chemical methods. They cannot replicate, requiring multiple doses to evoke an immune response, which is mostly humoral. Inactivated vaccines are safer, especially for immunocompromised individuals, and more stable, not requiring refrigeration. Examples are polio (Salk vaccine) and influenza vaccines. Both vaccine types play crucial roles in preventing various diseases, with their choice depending on factors like stability, safety, and the type of immune response required.
Comprehensive Preclinical Live Attenuated and Killed Vaccine Solutions
Creative Biolabs offers cutting-edge preclinical solutions for live attenuated and killed vaccines, combining traditional vaccine development approaches with advanced genetic engineering and analytical technologies. Our services are tailored to accelerate vaccine candidate validation, ensure safety, and optimize immunogenicity for diverse therapeutic targets, from infectious diseases to cancer.
Comprehensive Service Portfolio
Vaccine Design Adjuvant selection Analysis & ValidationFormulation Development Preclinical Testing
Customized Live Attenuated Vaccine Design
-
Precision Attenuation Strategy for Targets: Through gene editing or traditional passage techniques, specifically knock out virulence genes, while preserving antigenic integrity.
-
Multi-Epitope Integration: Based on the antigenic variation characteristics of pathogens, design multivalent attenuated vaccines. Achieve co-delivery of multiple antigens through bacterial vector systems, enhancing broad-spectrum immune protection.
Customized Killed Vaccine Design
-
Integration of Efficient Inactivation Technologies: Adopt methods such as formaldehyde inactivation, β-propiolactone treatment, or radiation inactivation to ensure complete inactivation of microorganisms while preserving key antigenic epitopes of pathogens.
-
Antigen Purification and Optimization: Purify immunogenic components of inactivated pathogens through chromatography techniques, remove impurities like endotoxins, and reduce the risk of adverse reactions.
Adjuvant Development & Optimization
-
Directed Regulation of Immune Responses: For live vaccines, use TLR agonists (CpG ODN) or IL-12 adjuvants to boost Th1 responses and memory T cells. For killed vaccines, employ Alum (aluminum hydroxide) or MF59 adjuvants to elevate neutralizing antibodies via APC activation.
-
Mechanistic Validation and Screening: Use in vitro PBMC stimulation assays and mouse/non-human primate models to evaluate the impact of adjuvants on vaccine antigen presentation efficiency and immune memory duration, and screen optimal adjuvant combinations.
Analytical Development & Preclinical Validation
-
Quality Control: CFU counting, qPCR for virulence gene stability in live vaccines; TCID50 and Limulus assays for inactivation/safety in killed vaccines.
-
Immunogenicity: In vitro cytokine (IFN-γ/IL-4) and antibody subtype (IgG1/IgG2a) detection; in vivo neutralizing antibody titers and tissue protection via challenge models.
-
Safety: Virulence reversion testing in immunodeficient models for live vaccines; local irritation/systemic toxicity assays for killed vaccines.
Formulation Development & Process Scale-up
-
Stability: Lyophilization protectants (trehalose-mannitol) for live vaccines; pH buffers/antioxidants (vitamin E) prevent antigen aggregation in killed vaccines.
-
Scalable Production: 50–2000 L fermenters with continuous inactivation systems; chromatography (e.g., Protein A) and lyophilization lines for large-scale purification.
Comprehensive Efficacy & Safety Validation
We conduct rigorous in vivo efficacy studies using validated animal models (rodents, non-human primates), featuring challenge trials with live pathogens and multiplex immunoassays to quantify protective immunity (neutralizing antibodies, T-cell responses).
Getting Started with Your Bacterial Vaccine Project
Contact us via form submission or email us to discuss your project–we will promptly follow up with you.
Professional Vaccine Solution platform
Why Choose our Live Attenuated and Killed Vaccines Services?
Enhanced Immunogenicity via Multidimensional Immunity
Live attenuated vaccines leverage optimized viral vectors (e.g., dual-attenuated influenza platforms) to stimulate robust mucosal IgA, systemic IgG, and T-cell responses, outperforming injectable vaccines in cross-protection against variants.
Broad-Spectrum Protection for Challenging Antigens
Proprietary DNA immunization (e.g., Magic™ technology) and reverse genetics enable high-efficiency delivery of hard-to-express antigens (e.g., transmembrane proteins, toxic antigens), eliciting antibodies against native structures.
Accelerated Timeline from Design to Clinic
Integrated platforms combine AI-assisted antigen design with toxicology (e.g., single-dose rodent studies) and QC analytics, cutting development time by 40% versus conventional pathways.
Dual Safety and Cost Efficiency
Killed vaccines employ high-fidelity purification and adjuvant systems (e.g., MF59), reducing adverse events to <20% (vs. 29–100% industry average) while enabling room-temperature storage.
Available Products
Antigen Products
Creative Biolabs offers ready-to-use bacterial or viral antigens to accelerate research timelines, while also providing customized antigen solutions tailored to specific experimental needs upon request
Antibody Products
To help clients reduce research time, Creative Biolabs provides ready-to-use bacterial and viral antibodies. We also offer custom antibody synthesis if you have specific requirements.
FAQs About Our Live Attenuated and Killed Vaccine Solution
-
What are the key considerations when designing live attenuated vaccines?
Designing live attenuated vaccines requires careful attenuation of the pathogen to ensure it remains immunogenic but non-virulent. Factors such as stability, mutation risk, host immune response, and temperature sensitivity must be considered. The pathogen must effectively stimulate the immune system without causing disease, ensuring safety while providing strong, lasting immunity.
-
What are the main challenges in the development of killed vaccines?
The primary challenges in killed vaccine development include ensuring the complete inactivation of the pathogen while retaining its immunogenic properties. Achieving the right balance between immunogenicity and safety can be difficult, and killed vaccines often require adjuvants and multiple doses to induce a sufficient immune response.
-
How does immune response differ between live attenuated and killed vaccines?
Live attenuated vaccines generally induce a strong, long-lasting immune response, often mimicking natural infection, which stimulates both humoral and cell-mediated immunity. Killed vaccines, in contrast, primarily elicit a humoral immune response, usually requiring booster doses and adjuvants to enhance their effectiveness.
-
What types of pathogens are best suited for live attenuated vaccine design?
Pathogens that are highly immunogenic and capable of being safely weakened without losing their ability to stimulate a robust immune response are ideal candidates for live attenuated vaccines. Viruses such as measles, mumps, and rubella are commonly used due to their ability to mimic natural infection without causing disease.
-
How are killed vaccines typically inactivated?
Killed vaccines are typically inactivated using physical or chemical methods, such as heat, formaldehyde, or radiation. These methods destroy the pathogen's ability to replicate while preserving its antigenic properties, allowing the immune system to recognize and respond to the inactivated pathogen without the risk of causing disease.
-
How do storage and transport requirements differ between live attenuated and killed vaccines?
Live attenuated vaccines are often more sensitive to temperature changes and require cold chain storage to maintain viability, limiting their use in regions with poor infrastructure. Killed vaccines are generally more stable and easier to store and transport, as they do not contain living organisms that need to be kept viable.
Related Resources
Online Inquiry
